報價延遲最少15分鐘:2025/08/11 05:57 EDT
盤前時段
|
||||
|
1.51 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.46
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.61/-1.18
|
|
企業價值
266.88M
|
| 資產負債 |
|
每股賬面淨值
1.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/11 05:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
